SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
ATLANTA, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's executive team will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference being held at the Langham Hotel on Tuesday, December 15, 2015 in Boston, MA.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company's ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase 1 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals, Inc.
CONTACT: Mark Colonnese
Executive Vice President and Chief Financial Officer
(678) 221-3352
[email protected]
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]
